FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387130006> ?p ?o ?g. }

• W4387130006 abstract "The diffuse large B-cell lymphoma (DLBCL) has the highest incidence of all lymphomas worldwide. To investigate the functions of lymphocyte activation gene 3 (LAG-3) and programmed cell death 1 (PD-1) in tissues and peripheral blood of patients with DLBCL, the expression of LAG-3 and PD-1 genes in DLBCL-TCGA were analyzed.LAG-3 and PD-1 mRNA levels in DLBCL were analyzed using data from The Cancer Genome Atlas (TCGA) database. Utilize the Genotype-Tissue Expression (GTEx) database for assessing the variance in the expression of LAG-3, PD-1, and other associated factors between the tissues of DLBCL patients and healthy individuals. Immunohistochemistry was applied to detect the expression of LAG-3 and PD-1 levels in 137 cases of DLBCL tissues and 20 cases of reactive lymphoid hyperplasia. The prognostic value of LAG-3 and PD-1 were assessed using the Kaplan-Meier curve. The Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) and ssGSEA algorithm were used to explore the immune microenvironment of DLBCL. Additionally, the expression and co-expression of LAG-3 and PD-1 were detected on CD4 and CD8 T cells in peripheral blood samples from 100 cases of DLBCL tissues and 30 cases of healthy individuals using flow cytometry.According to TCGA database, LAG-3 and PD-1 gene expression levels were significantly up-regulated in DLBCL tissues. LAG-3 and PD-1 levels were also strongly positively correlated with those of most infiltrating immune cells. Overall survival of patients with high LAG-3 and PD-1 co-expression was significantly shorter than that of patients with low co-expression. In DLBCL patients, LAG-3 and PD-1 were highly expressed in peripheral blood CD8+ T cells. In addition, LAG-3 was highly expressed in CD4+ T cells, while the expression of PD-1 in CD4+ T cells of DLBCL patients showed no significant difference compared to healthy individuals. Additionally, CD8+ T cells and SU-DHL6/OCI-LY3 from patients with DLBCL were co-cultured in vitro; after addition of LAG-3 and/or PD-1 inhibitors alone, an increased perforin and granzyme B secretion levels by CD8+ T cells were detected, as well as an increase in the overall proportion of tumor cells undergoing apoptosis.High LAG-3 and PD-1 levels significantly inhibit CD8+ T cell function, resulting in weakened ability to kill tumor cells. Combined LAG-3 and PD-1 blockade can restore CD8+ T cell function and provides a potential avenue for development of personalized cellular immunotherapy for DLBCL." @default.
• W4387130006 created "2023-09-29" @default.
• W4387130006 creator A5004448432 @default.
• W4387130006 creator A5008095269 @default.
• W4387130006 creator A5054866713 @default.
• W4387130006 creator A5062497413 @default.
• W4387130006 creator A5081417209 @default.
• W4387130006 creator A5090249848 @default.
• W4387130006 date "2023-09-28" @default.
• W4387130006 modified "2023-10-18" @default.
• W4387130006 title "Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells" @default.
• W4387130006 cites W2066599338 @default.
• W4387130006 cites W2072646319 @default.
• W4387130006 cites W2160834915 @default.
• W4387130006 cites W2310716991 @default.
• W4387130006 cites W2340751952 @default.
• W4387130006 cites W2403400382 @default.
• W4387130006 cites W2412725897 @default.
• W4387130006 cites W2484191422 @default.
• W4387130006 cites W2560367415 @default.
• W4387130006 cites W2577413745 @default.
• W4387130006 cites W2588916278 @default.
• W4387130006 cites W2593111137 @default.
• W4387130006 cites W2600581432 @default.
• W4387130006 cites W2610082331 @default.
• W4387130006 cites W2612422239 @default.
• W4387130006 cites W2744261860 @default.
• W4387130006 cites W2767931551 @default.
• W4387130006 cites W2781250194 @default.
• W4387130006 cites W2790574591 @default.
• W4387130006 cites W2794872274 @default.
• W4387130006 cites W2797429263 @default.
• W4387130006 cites W2807205254 @default.
• W4387130006 cites W2808293799 @default.
• W4387130006 cites W2808421749 @default.
• W4387130006 cites W2808698668 @default.
• W4387130006 cites W2909334052 @default.
• W4387130006 cites W2910269253 @default.
• W4387130006 cites W2945590213 @default.
• W4387130006 cites W2946060264 @default.
• W4387130006 cites W2946112461 @default.
• W4387130006 cites W2998900184 @default.
• W4387130006 cites W3001407138 @default.
• W4387130006 cites W3015860015 @default.
• W4387130006 cites W3016806376 @default.
• W4387130006 cites W3024880920 @default.
• W4387130006 cites W3088274952 @default.
• W4387130006 cites W3127620441 @default.
• W4387130006 cites W3163578171 @default.
• W4387130006 cites W4210735377 @default.
• W4387130006 cites W4225394054 @default.
• W4387130006 cites W4281395882 @default.
• W4387130006 cites W4385986623 @default.
• W4387130006 doi "https://doi.org/10.3389/fimmu.2023.1265255" @default.
• W4387130006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37841254" @default.
• W4387130006 hasPublicationYear "2023" @default.
• W4387130006 type Work @default.
• W4387130006 citedByCount "0" @default.
• W4387130006 crossrefType "journal-article" @default.
• W4387130006 hasAuthorship W4387130006A5004448432 @default.
• W4387130006 hasAuthorship W4387130006A5008095269 @default.
• W4387130006 hasAuthorship W4387130006A5054866713 @default.
• W4387130006 hasAuthorship W4387130006A5062497413 @default.
• W4387130006 hasAuthorship W4387130006A5081417209 @default.
• W4387130006 hasAuthorship W4387130006A5090249848 @default.
• W4387130006 hasBestOaLocation W43871300061 @default.
• W4387130006 hasConcept C154317977 @default.
• W4387130006 hasConcept C167672396 @default.
• W4387130006 hasConcept C16930146 @default.
• W4387130006 hasConcept C202751555 @default.
• W4387130006 hasConcept C203014093 @default.
• W4387130006 hasConcept C2777701055 @default.
• W4387130006 hasConcept C2778559949 @default.
• W4387130006 hasConcept C2779338263 @default.
• W4387130006 hasConcept C2781053074 @default.
• W4387130006 hasConcept C502942594 @default.
• W4387130006 hasConcept C55493867 @default.
• W4387130006 hasConcept C71924100 @default.
• W4387130006 hasConcept C86803240 @default.
• W4387130006 hasConcept C8891405 @default.
• W4387130006 hasConceptScore W4387130006C154317977 @default.
• W4387130006 hasConceptScore W4387130006C167672396 @default.
• W4387130006 hasConceptScore W4387130006C16930146 @default.
• W4387130006 hasConceptScore W4387130006C202751555 @default.
• W4387130006 hasConceptScore W4387130006C203014093 @default.
• W4387130006 hasConceptScore W4387130006C2777701055 @default.
• W4387130006 hasConceptScore W4387130006C2778559949 @default.
• W4387130006 hasConceptScore W4387130006C2779338263 @default.
• W4387130006 hasConceptScore W4387130006C2781053074 @default.
• W4387130006 hasConceptScore W4387130006C502942594 @default.
• W4387130006 hasConceptScore W4387130006C55493867 @default.
• W4387130006 hasConceptScore W4387130006C71924100 @default.
• W4387130006 hasConceptScore W4387130006C86803240 @default.
• W4387130006 hasConceptScore W4387130006C8891405 @default.
• W4387130006 hasLocation W43871300061 @default.
• W4387130006 hasLocation W43871300062 @default.
• W4387130006 hasOpenAccess W4387130006 @default.
• W4387130006 hasPrimaryLocation W43871300061 @default.
• W4387130006 hasRelatedWork W1497833379 @default.
• W4387130006 hasRelatedWork W1964266791 @default.

• next